Comparative Pharmacology
Head-to-head clinical analysis: DOXY 100 versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 100 versus VIBRAMYCIN.
DOXY 100 vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic